What is the scope and claim structure of U.S. Patent 4,537,883?
U.S. Patent 4,537,883, granted on August 20, 1985, covers a class of chemical compounds with specific therapeutic applications. The patent primarily claims a group of analogs derived from a core heterocyclic structure, with variations in substituents that influence pharmacological activity. It aims to protect compounds with potential use as anti-inflammatory, analgesic, or other therapeutic agents.
Key claims and scope details:
- Compound claims: Cover compositions of matter comprising specific chemical structures, including substituted heterocycles such as thiazoles and oxazoles, with particular substituents at designated positions.
- Method claims: Cover methods of synthesizing these compounds, emphasizing steps involved in preparing the heterocyclic cores with substituents that modulate activity.
- Use claims: Encompass methods of using the compounds for treating inflammatory conditions, pain, or related disorders, often linked to their pharmacologically active profile.
Structural scope:
The patent claims compounds characterized by a heterocyclic core (e.g., 1,3-thiazole or oxazole) attached to side chains with specific functional groups. Variations in substituents generally include alkyl, aryl, or halogen groups at defined positions, which impact binding affinity and pharmacokinetics.
Limitations:
The scope is limited to compounds with the claimed heterocyclic core and functional groups, excluding other heterocyclic classes or unrelated chemical entities. The patent's claims do not extend to different chemical moieties outside the disclosed structural patterns, nor do they claim the pharmacological effects independently of the compounds claimed.
How does the patent landscape look for similar compounds and therapeutic claims?
Patent landscape overview:
The patent landscape around this patent involves multiple filings across pharmaceuticals and chemical synthesis. Key aspects include:
- Origin of related patents: Numerous patents citing or building upon U.S. 4,537,883, particularly in the fields of heterocyclic pharmaceuticals and anti-inflammatory agents.
- Expiration date: The patent expired on August 20, 2002, after 17 years from issue, opening the compound space for generic development and manufacturing.
Major patent families citing 4,537,883:
- European equivalents: E.P. 0 258 350 B1, claiming similar heterocycles with anti-inflammatory properties.
- Japanese filings: JP 61-169511 and related patents, elaborating on synthesis methods and broader compound classes.
- Follow-on patents: Focused on formulation, specific therapeutic use, or refined synthesis methods, often filed during or after the patent's enforceable period.
Patent scope limitations:
While the core compounds are now off patent, related applications that modify substituents, formulations, or delivery methods remain under varying patent protection. These later patents typically aim to extend patent life or carve out novel therapeutic niches based on the original compounds.
Patent challenges and legal status:
Historically, 4,537,883 was subject to legal challenges regarding patentability of the claims, especially based on prior art disclosures. Its expiration has shifted the competitive landscape towards generic manufacturers, with patent linkage now more relevant to newer inventions related to this core scaffold.
What are the key trends in the patent landscape for this chemical class?
- Focus on pharmacokinetics: Recent patents show an emphasis on optimizing bioavailability and reducing side effects.
- Formulation innovations: Extended patent protection often involves sustained-release formulations or targeted delivery systems based on the original compounds.
- Combination therapies: Patents now cover the use of these heterocycles in combination with other drug classes, such as NSAIDs or corticosteroids.
- Synthesis improvements: Encompass greener, more efficient synthetic routes, which can reduce costs and improve yield.
What implications does this patent landscape have for current drug development?
- Generic development: After patent expiration in 2002, companies have introduced generic versions of drugs based on the core compounds.
- Patent thickets: Firms involved in formulation enhancements or new therapeutic uses may still maintain patent protection, creating barriers for biosimilar or generic entrants.
- Research focus: Ongoing patent filings indicate continued interest in modifying the original scaffold for improved efficacy, safety, and delivery.
Key Takeaways
- U.S. Patent 4,537,883 claims heterocyclic compounds with potential anti-inflammatory and analgesic uses, focusing on specific substituted thiazoles and oxazoles.
- The patent's expiration in 2002 led to subsequent generic market entries; however, further patents on formulations and uses persist.
- The compound class remains relevant in drug development, with recent patents emphasizing pharmacokinetic improvements and combination therapies.
- Legal challenges to the patent's validity occurred but did not prevent eventual expiration.
- The overall patent landscape indicates a transition from core compound protection to innovation in formulations, delivery systems, and expanded therapeutic applications.
FAQs
1. Are there existing patents that cover the same compounds as U.S. 4,537,883?
No. The patent expired in 2002, but related patents on formulations, uses, and synthesis methods may still be in force, depending on jurisdiction and claim scope.
2. What are the primary therapeutic applications associated with these compounds?
They are primarily used or investigated for anti-inflammatory, analgesic, and related pharmacological activities.
3. Can I develop a drug based on the same core structure without infringing on this patent?
Yes. Since the patent expired, developing drugs with these compounds is legal, but ensuring no later patents cover specific formulations or uses is essential.
4. How does the patent landscape influence current R&D efforts?
The expiration of core compounds shifts focus to formulation innovations, combination therapies, and targeted delivery systems, which are still eligible for patent protection.
5. Is there ongoing litigation related to this patent?
There are no widely reported ongoing litigations; the patent's expiration has minimized legal risks for generic manufacturers.
Sources
[1] U.S. Patent and Trademark Office. Patent 4,537,883.
[2] European Patent Office. Related patent documents.
[3] Japanese Patent Office filings.
[4] Patent legal case histories.
